OncoMatch/Colorectal Cancer (CRC)/MSH2
Colorectal Cancer (CRC)MSH2 Clinical Trials
MSH2 is one of four mismatch repair proteins assessed by IHC; loss of MSH2 defines deficient MMR (dMMR) and predicts MSI-H status, qualifying patients for checkpoint immunotherapy. dMMR CRC responds dramatically to PD-1 blockade — pembrolizumab is first-line standard for dMMR metastatic CRC. Trials explore neoadjuvant immunotherapy, combination checkpoint approaches, and MSI as a predictive biomarker across treatment lines.
Top recruiting MSH2 Colorectal Cancer (CRC) trials
Ranked by phase and US site count. See all 43 trials matched to your profile →
Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Sun Yat-sen University
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
Centre Hospitalier Universitaire de Besancon
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
Jun Huang
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer
Sir Run Run Shaw Hospital
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Sun Yat-sen University
Browse other molecular targets with active Colorectal Cancer (CRC) trials.